Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

Míreanna comhchosúla

• Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
  de réir: Yuncheng Bei (16546095)
  Foilsithe / Cruthaithe: (2025)
• Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
  de réir: Yuncheng Bei (16546095)
  Foilsithe / Cruthaithe: (2025)
• Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
  de réir: Sheheryar Kabraji (15050565)
  Foilsithe / Cruthaithe: (2025)
• Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
  de réir: Amr El Zawily (14851115)
  Foilsithe / Cruthaithe: (2025)
• Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
  de réir: Amr El Zawily (14851115)
  Foilsithe / Cruthaithe: (2025)